Theory of mind develops surprisingly early, a book publisher doubles down in defense of a controversial author, and false vaccine news gets a correction.

Mice with the mutations linked to tuberous sclerosis make too little protein in their brains — a finding that contradicts a leading theory about the condition.

The drug rapamycin, which is in clinical trials as a treatment for tuberous sclerosis, may exacerbate features of fragile X syndrome, another condition related to autism.

Common genetics may help forge social ties, a nonspeaking woman with autism hosts “The Late Show,” and the mix of bacteria in the gut may relate to brain structure.

Male mice with a genetic variant tied to autism may have learning difficulties that females with the variant do not.

An interview for diagnosing adults on the spectrum clears its first hurdle, a fragile X drug eases multiple features of the syndrome in a mouse model, and a brain bank chronicles the beautiful diversity of neurons.

The drug mavoglurant has no effect on a brain circuit involved in social behavior in a mouse model of fragile X syndrome. That may explain its poor performance in people with the condition.

A drug that selectively blocks one form of an enzyme called GSK-3 prevents seizures and improves cognitive deficits in a mouse model of fragile X syndrome.

Researchers have used transcranial magnetic stimulation to show that people with fragile X syndrome have weak ‘inhibitory’ signals, those that dampen neuronal activity in the brain.

Sleep problems in autism may stem from the same biological changes that underlie the core features of the condition.